No Data
Paulette: 2024 Annual Report
Paulette: First quarter report 2025
Paulette: 2024 Annual Report Summary
Guangdong Biolight Meditech Co., Ltd. (SZSE:300246) Held Back By Insufficient Growth Even After Shares Climb 33%
Southwest Securities: The stable trend of hemodialysis treatment rates is expected to improve the concentration of domestic consumables through centralized procurement.
The time for domestic substitution of equipment is right; under the centralized procurement policy, leading enterprises with strong supply capabilities have a high selection rate, and the concentration of the Industry is expected to increase.
Guangdong Biolight Meditech (300246.SZ): Cumulatively repurchased 1.1228% of shares.
Gelonghui, February 5: Guangdong Biolight Meditech (300246.SZ) announced that as of January 31, 2025, the company had cumulatively repurchased 2,970,600 shares of the company through a dedicated securities account for share repurchase via centralized bidding, accounting for 1.1228% of the company's total share capital; the highest Fill Price was 7.07 RMB/share, the lowest Fill Price was 6.31 RMB/share, and the total amount paid was 20,007,148.50 RMB (excluding stamp duty, trading commission, and other transaction costs). This share repurchase by the company complies with the relevant laws and regulations.
The Market Doesn't Like What It Sees From Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Revenues Yet As Shares Tumble 26%
